المؤلفون: Zhang, Shannon, Lee, Jessica, Tukachinsky, Hanna, Schrock, Alexa, Nagasaka, Misako, Ou, Sai-Hong

المصدر: JTO Clinical and Research Reports. 3(9)

مصطلحات موضوعية: Actionable driver mutation, EGFR, Germline CHEK2 mutation, KRAS, NSCLC, Plasma genotyping, Tumor genotyping

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/39b251t1Test

المؤلفون: Danuta Gąsior-Perczak, Artur Kowalik, Janusz Kopczyński, Paweł Macek, Kornelia Niemyska, Agnieszka Walczyk, Krzysztof Gruszczyński, Monika Siołek, Tomasz Dróżdż, Marcin Kosowski, Iwona Pałyga, Piotr Przybycień, Olga Wabik, Stanisław Góźdź, Aldona Kowalska

المصدر: Cancers, Vol 16, Iss 4, p 815 (2024)

مصطلحات موضوعية: papillary thyroid cancer, CHEK2 mutation, checkpoint kinase 2, p53, TP53 gene, immunohistochemistry, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://www.mdpi.com/2072-6694/16/4/815Test; https://doaj.org/toc/2072-6694Test

الوصول الحر: https://doaj.org/article/d55e709c11874962823c7f2715682fbbTest

المؤلفون: Abraham Ipe, Anne Angiolillo, David Jacobsohn, Jinjun Cheng, Miriam Bornhorst, Joyce Turner, Anant Vatsayan

المصدر: Frontiers in Pediatrics, Vol 11 (2023)

مصطلحات موضوعية: CAR-T, tisagenlecleucel, B-ALL, CHEK2 mutation, MDS, Pediatrics, RJ1-570

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/fped.2023.1067131/fullTest; https://doaj.org/toc/2296-2360Test

الوصول الحر: https://doaj.org/article/4ad77411f95d435ba7d2e6d5c8644932Test

المؤلفون: A. I. Stukan, A. Yu. Goryainova, M. M. Grigoryan, V. F. Kutyan, V. S. Zhdanov, T. Yu. Semiglazova, E. N. Imyanitov, А. И. Стукань, А. Ю. Горяинова, М. М. Григорян, В. Ф. Кутян, В. С. Жданов, Т. Ю. Семиглазова, Е. Н. Имянитов

المساهمون: The study was performed with the support of Russian Science Foundation (grant No. 21-75-30015)., Исследование проведено при поддержке Российского научного фонда (грант № 21-75-30015).

المصدر: Cancer Urology; Том 19, № 1 (2023); 85-101 ; Онкоурология; Том 19, № 1 (2023); 85-101 ; 1996-1812 ; 1726-9776

مصطلحات موضوعية: резистентность к антиандрогенам 2-го поколения, mutation of homologous recombination repair genes, HRR, BRCA1/2 -mutation, CHEK2 -mutation, enzalutamide, resistance to second-generation antiandrogenes, мутации генов репарации ДНК путем гомологичной рекомбинации, мутация BRCA1/2, мутация CHEK2, энзалутамид

وصف الملف: application/pdf

العلاقة: https://oncourology.abvpress.ru/oncur/article/view/1695/1442Test; Sung H., Ferlay J., Siegel R.L. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71(3):209—49. DOI:10.3322/caac.21660; Sartor O., de Bono J.S. Metastatic prostate cancer. N Engl J Med 2018;378(17):1653-4. DOI:10.1056/NEJMra1803343; Beer T.M., Armstrong A.J., Rathkopf D.E. et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371(5):424-33. DOI:10.1056/NEJMoa1405095; Scher H.I., Fizazi K., Saad F. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367(13):1187-97. DOI:10.1056/NEJMoa1207506; Conteduca V., Wetterskog D., Sharabiani M.T.A. et al. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study. Ann Oncol 2017;28(7):1508-16. DOI:10.1093/annonc/mdx155; Antonarakis E.S., Lu C., Wang H. et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014;371(11):1028-38. DOI:10.1056/NEJMoa1315815; Armstrong A.J., Halabi S., Luo J. et al. Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the prophecy study. J Clin Oncol 2019;37(13):1120-9. DOI:10.1200/JCO.18.01731; Liu C., Lou W., Zhu Y. et al. Intracrine androgens and AKR1C3 activation confer resistance to enzalutamide in prostate cancer. Cancer Res 2015;75(7):1413-22. DOI:10.1158/0008-5472.CAN-14-3080; Crona D.J., Whang Y.E. Androgen receptor-dependent and -independent mechanisms involved in prostate cancer therapy resistance. Cancers 2017;9(6):67. DOI:10.3390/cancers9060067; Guedes L.B., Morais C.L., Almutairi F. et al. Analytic valida of RNA in situ hybridization (RISH) for AR and AR-V7 exp ression in human prostate cancer. Clin Cancer Res 2016;22(18):4651-63. DOI:10.1158/1078-0432.CCR-16-0205; Salma B.S., Varadha B.V., Hannelore V.H. et al. Novel insights in cell cycle dysregulation during prostate cancer progression. Endocr Relat Cancer 2021;28(6):R141-55. DOI:10.1530/ERC-20-0517; Mcnair C., Urbanuccia A., Comstock C.E. et al. Cell cycle-coupled expansion of AR activity promotes cancer progression. Oncogene 2017;36(12):1655-68. DOI:10.1038/onc.2016.334; Schiewer M.J., Augello M.A., Knudsen K.E. The AR dependent cell cycle: mechanisms and cancer relevance. Mol Cell Endocrinol 2012;352(1-2):34-45. DOI:10.1016/j.mce.2011.06.033; Gordon V., Bhadel S., Wunderlich W. et al. CDK9 regulates AR promoter selectivity and cell growth through serine 81 phosphorylation. Mol Endocrinol 2010;24(12):2267-80. DOI:10.1210/me.2010-0238; Chen S., Gulla S., Cai C., Balk S.P. Androgen receptor serine 81 phosphorylation mediates chromatin binding and transcriptional activation. J Biol Chem 2012;287(11):8571-83. DOI:10.1074/jbc.m111.325290; Koryakina Y., Knudsen K.E., Gloeli D. Cell-cycle-dependent regulation of androgen receptor function. Endocr Relat Cancer 2015;22(2):249-64. DOI:10.1530/ERC-14-0549; Cancer Genome Atlas Research Network. The molecular taxonomy of primary prostate. Cancer Cell 2015;163(4):1011-25. DOI:10.1158/1538-7445.am2016-133; Ren S., Wei G.H., Liu D. et al. Wholegenome and transcriptome sequencing of prostate cancer identify new genetic alterations driving disease progression. Eur Urol 2018;73(3):322-39. DOI:10.21236/ada613308; Fraser M., Sabelnykova V.Y., Yamaguchi T.N. et al. Genomic hallmarks of localized, non-indolent prostate cancer. Nature 2017;541(7637):359-64. DOI:10.1016/j.juro.2017.09.039; Bangma C.H., Roobol M.J. Defining and predicting indolent and low risk prostate cancer. Crit Rev Oncol Hematol 2012;83(2):235-41. DOI:10.1016/j.critrevonc.2011.10.003; Irshad S., Bansal M., Castillo-Martin M. et al. A molecular signature predictive of indolent prostate cancer. Sci Transl Med 2013;5(202):202ra122. DOI:10.1126/scitranslmed.3006408; Kamoun A., Cancel-Tassin G., Fromont G. et al. Comprehensive molecular classification of localized prostate adenocarcinoma reveals a tumour subtype predictive of non-aggressive disease. Ann Oncol 2018;29(8):1814-21. DOI:10.1093/annonc/mdy224; Bancroft E.K., Page E.C., Castro E. et al. Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the Impact study. Eur Urol 2014;66(3):489-99. DOI:10.1126/scitranslmed.3006408; Zhang W., Van Gent D.C., Incrocci L. et al. Role of the DNA damage response in prostate cancer formation, progression and treatment. Prostate Cancer Prostatic Dis 2020;23(1):24-37. DOI:10.1038/s41391-019-0153-2; Hussain M., Fizazi K., Saad F. et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med 2018;378(26):2465-74. DOI:10.1056/NEJMoa1800536; Edwards J., Krishna N.S., Grigor K.M., Bartlett J.M.S. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 2003;89(3):552-6. DOI:10.1038/sj.bjc.6601127; Romanel A., Gasi Tandefelt D., Conteduca V. et al. Plasma AR and abiraterone-resistant prostate cancer. Sci Transl Med 2015;7(312):re10. DOI:10.1126/scitranslmed.aac9511; Tucci M., Zichi C., Buttigliero C. et al. Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions. Onco Targets Ther 2018;11:7353-68. DOI:10.2147/OTT.S153764; Teply B.A., Wang H., Luber B. et al. Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. Lancet Oncol 2018;19(1):76-86. DOI:10.1016/S1470-2045(17)30906-3; Joseph J.D., Lu N., Qian J. et al. A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discov 2013;3(9):1020-9. DOI:10.1158/2159-8290.CD-13-0226; Balbas M.D., Evans M.J., Hosfield D.J. et al. Overcoming mutation-based resistance to antiandrogens with rational drug design. Elife 2013;2:e00499. DOI:10.7554/elife.00499; Lallous N., Volik S.V., Awrey S. et al. Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients. Genome Biol 2016;17(1):10. DOI:10.1186/s13059-015-0864-1; Hu R., Dunn T.A., Wei S. et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 2009;69(1):16-22. DOI:10.1158/0008-5472.CAN-08-2764; Zhang X., Morrissey C., Sun S. et al. Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS One 2011;6(11):e27970. DOI:10.1371/journal.pone.0027970; Ware K.E., Garcia-Blanco M.A., Armstrong A.J., Dehm S.M. Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer. Endocr Relat Cancer 2014;21(4):T87-103. DOI:10.1530/erc-13-0470; Hu R., Lu C., Mostaghel E.A. et al. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res 2012;72(14):3457-62. DOI:10.1158/0008-5472.CAN-11-3892; Sq T., Kwan E., Fettke H. AR-V7 and AR-V9 expression is not predictive of response to AR-axis targeting agents in metastatic castration-resistant prostate cancer. Cancer Res 2018;78(13):2593. DOI:10.1158/1538-7445.am2018-2593; Miller W.L., Auchus R.J. The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr Rev 2011;32(1):81-151. DOI:10.1210/er.2010-0013; Cai C., Balk S.P. Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy. Endocr Relat Cancer 2011;18(5):R175-82. DOI:10.1530/ERC-10-0339; Galletti G., Leach B.I., Lam L., Tagawa S.T. Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer. Cancer Treat Rev 2017;57:16-27. DOI:10.1016/j.ctrv.2017.04.008; Stanbrough M., Bubley G.J., Ross K. et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006;66(5):2815-25. DOI:10.1158/0008-5472.CAN-05-4000; Puhr M., Hoefer J., Eigentler A. et al. The glucocorticoid receptor is a key player for prostate cancer cell survival and a target for improved antiandrogen therapy. Clin Cancer Res 2018;24(4):927-38. DOI:10.1158/1078-0432.ccr-17-0989; Arora V.K., Schenkein E., Murali R. et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 2013;155(6):1309-22. DOI:10.1016/j.cell.2013.11.012; Venkitaraman R., Lorente D., Murthy V. et al. A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer. Eur Urol 2015;67(4):673-9. DOI:10.1016/j.eururo.2014.10.004; Akamatsu S., Inoue T., Ogawa O., Gleave M.E. Clinical and mo-lecular features of treatment-related neuroendocrine prostate cancer. Int J Urol 2018;25(4):345-51. DOI:10.1111/iju.13526; Flechon A., Pouessel D., Ferlay C. et al. Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial. Ann Oncol 2011;22(11):2476-81. DOI:10.1093/annonc/mdr004; Culine S., El Demery M., Lamy P.J. et al. Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers. J Urol 2007;178(3 Pt 1): 844-8. DOI:10.1016/j.juro.2007.05.044; McKay R.R., Kwak L., Crowdis J.P. Phase II multicenter study of enzalutamide in metastatic castration-resistant prostate cancer to identify mechanisms driving resistance. Clin Cancer Res 2021;27(13):3610-9. DOI:10.1158/1078-0432.CCR-20-4616; Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011;144(5):646-74. DOI:10.1016/j.cell.2011.02.013; Ceccaldi R., Rondinelli B., D'Andrea A.D. Repair pathway choices and consequences at the double-strand break. Trends Cell Biol 2015;26(1):52-64. DOI:10.1016/j.tcb.2015.07.009; Bhattacharjee S., Nandi S. Choices have consequences: The nexus between DNA repair pathways and genomic instability in cancer. Clin Transl 2016;5(1):45. DOI:10.1186/s40169-016-0128-z; Hustedt N., Durocher D. The control of DNA repair by the cell cycle. Nat Cell Biol 2016;19(1):1-9. DOI:10.1038/ncb3452; Jeggo P.A., Pearl L.H., Carr A.M. DNA repair, genome stability and cancer: a historical perspective. Nat Rev Cancer 2016;16(1):35-42. DOI:10.1038/nrc.2015.4; Roos W.P., Thomas A.D., Kaina B. DNA damage and the balance between survival and death in cancer biology. Nat Rev Cancer 2016;16(1):20-33. DOI:10.1038/nrc.2015.2; Schiewer M.J., Knudsen K.E. DNA damage response in prostate cancer. Cold Spring Harb Perspect Med 2019;9(1):a030486. DOI:10.1101/cshperspect.a030486; Robinson D., van Allen E.M., Wu Y.M. et al. Integrative clinical genomics of advanced prostate cancer. Cell 2015;161(5):1215-28. DOI:10.1016/j.cell.2015.05.001; Annala M., Vandekerkhove G., Khalaf D. et al. Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer. Cancer Discov 2018;8(4):444-57. DOI:10.1158/2159-8290.CD-17-0937; Thangavel C., Boopathi E., Liu Y. et al. RB loss promotes prostate cancer metastasis. Cancer Res 2017;77(4):982-95. DOI:10.1158/0008-5472.CAN-16-1589; Ku S.Y., Rosario S., Wang Y. et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science 2017;355(6320):78-83. DOI:10.1126/science.aah4199; McNair C., Xu K., Mandigo A.C. et al. Differential impact of RB status on E2F1 reprogramming in human cancer. J Clin Invest 2018;128(1):341-58. DOI:10.1172/JCI93566; Abida W., Cyrta J., Heller G. et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci USA 2019;116(23):11428-36. DOI:10.1073/pnas.1906812116; Annala M., Struss W.J., Warner E.W. et al. Treatment outcomes and tumor loss of heterozygosity in germline DNA repair-deficient prostate cancer. Eur Urol 2017;72(1):34-42. DOI:10.1016/j.eururo.2017.02.023; Chakraborty G., Armenia J., Mazzu Y.Z. et al. Significance of BRCA2 and RB1 co-loss in aggressive prostate cancer progression. Clin Cancer Res 2020;26(8):2047-64. DOI:10.1158/1078-0432.CCR-19-1570.; Матвеев В.Б., Киричек А.А., Филиппова М.Г. и др. Влияние герминальных мутаций в генах BRCA2 и CHEK2 на время до развития кастрационной резистентности у больных метастатическим гормоночувствительным раком предстательной железы. Урология 2019;(5):79-85. DOI:10.18565/urology.2019.5.79-85; Матвеев В.Б., Киричек А.А., Савинкова А.В. и др. Влияние герминальных мутаций в гене CHEK2 на выживаемость до биохимического рецидива и безметастатическую выживаемость после радикального лечения у больных раком. Онкоурология 2018;14(4):53-67. DOI:10.17650/1726-9776-2018-14-4-53-67; https://oncourology.abvpress.ru/oncur/article/view/1695Test

الإتاحة: https://doi.org/10.17650/1726-9776-2023-19-1-85-101Test
https://doi.org/10.3322/caac.21660Test
https://doi.org/10.1056/NEJMra1803343Test
https://doi.org/10.1056/NEJMoa1405095Test
https://doi.org/10.1056/NEJMoa1207506Test
https://doi.org/10.1093/annonc/mdx155Test
https://doi.org/10.1056/NEJMoa1315815Test
https://doi.org/10.1200/JCO.18.01731Test
https://doi.org/10.1158/0008-5472.CAN-14-3080Test
https://doi.org/10.3390/cancers9060067Test

المؤلفون: Shannon S. Zhang, MD, Jessica K. Lee, MSc, Hanna Tukachinsky, PhD, Alexa B. Schrock, PhD, Misako Nagasaka, MD, PhD, Sai-Hong Ignatius Ou, MD, PhD

المصدر: JTO Clinical and Research Reports, Vol 3, Iss 9, Pp 100387- (2022)

مصطلحات موضوعية: Germline CHEK2 mutation, Actionable driver mutation, NSCLC, EGFR, KRAS, Tumor genotyping, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: http://www.sciencedirect.com/science/article/pii/S2666364322001114Test; https://doaj.org/toc/2666-3643Test

الوصول الحر: https://doaj.org/article/e5774861fb6d4b509b5508a9a6e29a18Test

المؤلفون: Ipe, Abraham, Angiolillo, Anne, Wills, Melissa, Wyche, Erica, Jacobsohn, David, Cheng, Jinjun, Bornhorst, Miriam, Turner, Joyce, Vatsayan, Anant

المصدر: GW Research Showcase 2021-

مصطلحات موضوعية: CHEK2 Mutation, Tisagenlecleucel, Papillary Thyroid Carcinoma, Medicine and Health Sciences

وصف الملف: application/pdf

العلاقة: https://hsrc.himmelfarb.gwu.edu/gw_research_showcase/2022/medstudent/24Test; https://hsrc.himmelfarb.gwu.edu/cgi/viewcontent.cgi?article=1127&context=gw_research_showcaseTest

الإتاحة: https://hsrc.himmelfarb.gwu.edu/gw_research_showcase/2022/medstudent/24Test
https://hsrc.himmelfarb.gwu.edu/cgi/viewcontent.cgi?article=1127&context=gw_research_showcaseTest

المؤلفون: Shefali Khanna, Deena Dahshan, Erin Fankhanel, Doreen Griswold, Lynne J. Goebel

المصدر: Marshall Journal of Medicine, Vol 6, Iss 1, Pp 9-12 (2020)

مصطلحات موضوعية: rectal carcinoid, chek2 mutation, rectal neuroendocrine tumor, Medicine (General), R5-920

وصف الملف: electronic resource

العلاقة: https://mds.marshall.edu/cgi/viewcontent.cgi?article=1247&context=mjmTest; https://doaj.org/toc/2379-9536Test

الوصول الحر: https://doaj.org/article/1dc6d98d7ee7402db5a28e99c3327936Test

المؤلفون: Khanna, Shefali, Dahshan, Deena, Fankhanel, Erin, Griswold, Doreen, Goebel, Lynne J.

المصدر: Marshall Journal of Medicine

مصطلحات موضوعية: rectal carcinoid, CHEK2 mutation, rectal neuroendocrine tumor, Medicine and Health Sciences, Neoplasms

وصف الملف: application/pdf

العلاقة: https://mds.marshall.edu/mjm/vol6/iss1/4Test; https://mds.marshall.edu/context/mjm/article/1247/viewcontent/1247_Reformatted.pdfTest

الإتاحة: https://doi.org/10.33470/2379-9536.1247Test
https://mds.marshall.edu/mjm/vol6/iss1/4Test
https://mds.marshall.edu/context/mjm/article/1247/viewcontent/1247_Reformatted.pdfTest

المؤلفون: Ipe, Abraham, Angiolillo, Anne, Jacobsohn, David, Cheng, Jinjun, Bornhorst, Miriam, Turner, Joyce, Vatsayan, Anant

المصدر: GW Authored Works

مصطلحات موضوعية: B-ALL, CAR-T, CHEK2 mutation, MDS, tisagenlecleucel

العلاقة: https://hsrc.himmelfarb.gwu.edu/gwhpubs/2630Test; https://doi.org/10.3389/fped.2023.1067131Test

الإتاحة: https://doi.org/10.3389/fped.2023.1067131Test
https://hsrc.himmelfarb.gwu.edu/gwhpubs/2630Test

المؤلفون: Danuta Gąsior-Perczak, Artur Kowalik, Agnieszka Walczyk, Monika Siołek, Krzysztof Gruszczyński, Iwona Pałyga, Estera Mikina, Tomasz Trybek, Janusz Kopczyński, Ryszard Mężyk, Stanisław Góźdź, Aldona Kowalska

المصدر: Cancers; Volume 11; Issue 11; Pages: 1744

مصطلحات موضوعية: papillary thyroid cancer, BRAF mutation, CHEK2 mutation, risk stratification, response to therapy

وصف الملف: application/pdf

العلاقة: https://dx.doi.org/10.3390/cancers11111744Test

الإتاحة: https://doi.org/10.3390/cancers11111744Test